Definition of Orphan Drugs and its regulation

Orphan drugs refer to medications designated by regulatory authorities, such as the Ministry of Food and Drug Safety (MFDS) in South Korea, for specific rare conditions. These include:

1. Drugs used to diagnose or treat rare diseases under the Rare Disease Management Act.
2. Medications for conditions with no alternatives or significantly improved safety/effectiveness compared to existing options.

Criteria for Designation

1. Rare Diseases: For conditions with less than 20,000 patients nationwide.
2. Improved Safety/Efficacy: Alternatives either unavailable or inferior.
3. Clinical Development: Drugs under active clinical trials or supported by nonclinical evidence.
4. Supply Necessity: Critical for patients due to limited availability.

How to Apply for Orphan Drug Designation

1. Who Can Apply?
   Manufacturers, marketing authorization holders, importers, or individuals with clinical trial plans approved under the Pharmaceutical Affairs Act.
   
   
2. Application Process:
   Submit the Orphan Drug Application Form (Form 1) to the Ministry of Food and Drug Safety (MFDS) with required documentation.
   
   
3. Required Documents:
   • Proof of orphan drug designation
   • Recommendation letter from relevant medical associations or rare disease organizations
   • Clinical and nonclinical data, including toxicity results
   • Risk management plan and drug usage guidelines
4. Evaluation & Outcome:
   • MFDS reviews applications via an Orphan Drug Committee.
   • Approved drugs are published on MFDS's website.
   • Safety monitoring and re-evaluation occur every three years.